Damora Therapeutics, Inc. quarterly report, Q3 FY2023

Business Context and Reporting Period

The filing is Galecto, Inc.’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2023, filed November 6, 2023. The request metadata identifies Damora Therapeutics, Inc., but the filing text identifies the registrant as Galecto, Inc. (Nasdaq: GLTO), a clinical-stage biotechnology company developing small-molecule therapies targeting galectin-3 and LOXL2 in fibrotic diseases and cancer.

Galecto has no approved products and has generated no product revenue. Its primary candidates are GB1211, being evaluated in liver cirrhosis and oncology, and GB2064, being evaluated in myelofibrosis.

Financial Performance and Position

MetricThree Months Ended September 30Nine Months Ended September 30
RevenueNo product revenueNo product revenue
Research and development expense$2.6 million, down 75.7%$21.0 million, down 43.9%
General and administrative expense$3.3 million, up 5.6%$9.5 million, down 7.2%
Restructuring costs$2.7 million$2.7 million
Total operating expenses$8.6 million, down 37.0%$33.2 million, down 30.3%
Net loss$8.1 million, or $0.30 per share$31.9 million, or $1.21 per share
Net cash used in operating activitiesNot separately presented$25.4 million

There is no meaningful revenue or operating margin to report because the Company has no product sales. Interest income and foreign exchange activity produced other income of $0.4 million in the quarter and $1.4 million for the nine-month period.

  • Cash and cash equivalents were $23.1 million at September 30, 2023, compared with $32.8 million at December 31, 2022.
  • Current marketable securities were $21.1 million, compared with $27.4 million at year-end 2022; total cash, cash equivalents and marketable securities were $44.2 million.
  • Total current assets were $47.1 million and current liabilities were $12.6 million. The filing reports no material debt financing; liabilities primarily consisted of accounts payable, accrued expenses and operating lease liabilities.
  • Stockholders’ equity was $37.4 million, compared with $61.8 million at December 31, 2022. Accumulated deficit was $249.6 million.
  • Cash flow from investing activities was positive $12.8 million, principally reflecting net sales of marketable securities. Financing activities provided $2.9 million from common-stock sales under the at-the-market program.

Material Changes Versus the Prior Comparable Period

  • Quarterly net loss improved by $5.6 million, or 40.7%, primarily because research and development spending declined by $7.9 million. The improvement was partly offset by $2.7 million of restructuring costs.
  • Nine-month net loss improved by $15.7 million, or 33.0%, primarily because research and development expense declined by $16.4 million. The nine-month period included $2.7 million of restructuring costs not present in the prior-year period.
  • Quarterly clinical and preclinical spending declined by $6.9 million, and nine-month spending declined by $15.3 million, reflecting discontinued or reduced clinical activities.
  • Operating cash burn decreased from $31.5 million to $25.4 million for the first nine months, while cash and cash equivalents declined by $9.8 million during the period.
  • The Company sold 1.46 million common shares under its ATM program during the first nine months, generating $2.9 million net proceeds.

Guidance, Outlook, Risks and Unusual Items

  • In August 2023, the Phase 2b GB0139 trial in idiopathic pulmonary fibrosis failed to meet its primary endpoint, and development of GB0139 was discontinued.
  • In September 2023, the Company announced a restructuring expected to eliminate approximately 70% of its workforce, or up to 29 positions. It recorded $2.7 million of restructuring charges and estimates total restructuring charges of approximately $3.4 million, with substantial completion expected by year-end 2023. A separate retention program provides up to $1.2 million of cash bonuses to certain remaining employees.
  • The Company initiated a review of strategic alternatives, including a merger, acquisition, business combination, liquidation, licensing transaction or asset sale. No definitive transaction or timetable has been approved, and management cautions that a transaction may not occur or may not benefit stockholders.
  • Part A of the GALLANT-1 trial of GB1211 plus atezolizumab was completed. The Company selected 100 mg twice daily for future oncology trials after safety events at the 200 mg dose. Part B will not be initiated because of the strategic review.
  • The Company plans to continue supplying GB1211 for an investigator-initiated Phase 2 trial in metastatic melanoma and head and neck cancer, expected to begin in early 2024, subject to available resources and external support.
  • Patient treatment in the MYLOX-1 trial of GB2064 was completed, with topline results expected in the fourth quarter of 2023. The Company stated that it did not currently plan additional GB2064 trials after that readout.
  • Management believes the $44.2 million of cash, cash equivalents and marketable securities at September 30, 2023 will fund operating and capital requirements through at least the next twelve months from the filing date. This estimate depends on assumptions that may prove incorrect and may change materially depending on the strategic review.
  • Nasdaq notified the Company that its stock had traded below the $1.00 minimum bid price for 30 consecutive business days. The initial compliance deadline was March 25, 2024, with potential for an additional compliance period subject to Nasdaq requirements.
  • Key risks include continued losses, the need for additional financing, clinical and regulatory failure, workforce attrition following the restructuring, inability to complete a strategic transaction, possible liquidation or dissolution, dilution, and Nasdaq delisting.
  • Management concluded that disclosure controls and procedures were effective at the reasonable assurance level, with no material change in internal control over financial reporting during the quarter.

Investor Verification Checklist

  • Verify the registrant identity: the supplied filing is for Galecto, Inc., not Damora Therapeutics, Inc.
  • Confirm the cash runway assumptions and the pace of cash use after the restructuring and strategic-alternative expenses.
  • Monitor whether a strategic transaction, licensing arrangement, asset sale or liquidation plan is announced and on what terms.
  • Review the final results of the MYLOX-1 GB2064 trial and the status and funding of the investigator-initiated GB1211 trial.
  • Assess the impact of discontinuing GB0139 and not initiating Part B of GALLANT-1 on the remaining pipeline value.
  • Track Nasdaq bid-price compliance and any reverse split, transfer or delisting actions.
  • Evaluate potential dilution from the ATM program, outstanding options and any future financing.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.